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Comparative Doses of Generic and Brand Name Inhaled Corticosteroids
Reassess uncontrolled asthma every 2 to 6 weeks until good control is achieved.
Use lowest dose needed to keep asthma well controlled. Consider step down if controlled for > 3 months

Dosing
ICS
Dose Ages 0-4 yrs

Dosing
Dosing
Ages 5-11 yrs Ages 12+ yrs

Nebules:
0.25-0.5 mg
Med: >0.5-1 mg
High: >1 mg:

180-360 mcg
>360-720 mcg
>720 mcg

180-540 mcg
>540-1080 mcg
>1080 mcg

Low:

80-160 mcg
>160-320 mcg
>320 mcg

80-240 mcg
>240-480 mcg
>480 mcg

High:

80-160 mcg
>160-320 mcg
>320 mcg

160-320 mcg
>320-640 mcg
>640 mcg

Low:
2x day Med:
High:

160 mcg
>160-480 mcg
>480 mcg

320 mcg
>320-640 mcg
>640 mcg

+ Salmeterol:
Low: 176 mcg
Advair HFA
2x day Med: >176-352 mcg

88-176 mcg
>176-352 mcg
>352 mcg

88-264 mcg
>264-440 mcg
>440 mcg

100-200 mcg
>200-400 mcg
>400 mcg

100-300 mcg
>300-500 mcg
>500 mcg

Monotherapy
Generic name Brand names Brand names
with LABA
No LABA:
Pulmicort

Budesonide
DPI
+/- Formoterol

No LABA:
Beclomethasone
Qvar
MDI

Rx

+ Formoterol:
Symbicort
2x day Low:

2x day Med:
High:

Ciclesonide
MDI

No LABA:
Alvesco

Flunisolide
MDI

No LABA:
Aerospan HFA

Fluticasone
Propionate
MDI

No LABA:
Flovent HFA

Low:

2x day Med:

High: >352 mcg

+/- Salmeterol

No LABA:
+ Salmeterol:
Low:
Flovent Diskus Advair Diskus
2x day Med:
ArmonAir
Airduo
High:
Wixela
No LABA:
+ Vilanterol:
Low:
1x day Med:
Arnuity Ellipta *Breo
*For 18+ yrs
High:

Fluticasone
Propionate
DPI
+/- Salmeterol

Fluticasone
Furoate
DPI
+/- Vilanterol

No LABA:
Asmanex

Mometasone
DPI
+/- Formoterol

+ Formoterol: 1x day Low:
Dulera
or
Med:
2x day High:

No low dose
100 mcg
>100 mcg
110 mcg
220-440 mcg
>440 mcg

110-220 mcg
>220-440 mcg
>440 mcg

Scan QR code Key points for patient and family education and self-management training:
for free patient
friendly asthma 1. Symptoms of asthma indicate "swelling" (inflammation) in lungs. Chronic inflammation causes "scarring"
over time (remodeling). Emphasize symptoms > twice a week can lead to permanent scarring in the lungs.
guide for
smartphone 2. Review medication types - Rescue and Control. Emphasize only control medication can "stop the scarring"

and protect long term lung functioning. Control medication takes days to weeks to work. Explain that
decreased swelling = fewer symptoms = less need for/dependence on SABA over time.
3.

Emphasize that asthma inhalers only work if taken correctly - "Get it in and keep it in." It is critical to explain,
model, and require return demonstration of inhaler technique over multiple visits. Use spacer for all ages.

4.

Help establish an easy to follow routine: Keep inhalers in high visibility/access locations (ex. with toothbrush).

5.

Encourage using a digital peak flow meter to help patient understand effect of inflammation in the lungs.

Mammen, J.R. (2021) University of Rhode Island. Adapted from Expert Panel Report (EPR) 3, EPR4 (2020 update) guidelines for management of asthma and the Global Initiative
for Asthma (GINA) 2020 Pocket Guide for Asthma Management and Prevention. This brief guide is a general summary and does not represent the entirety of the EPR3, EPR4 or
GINA guidelines. For additional details please refer to the full guidelines. Version date: 2/19/2021

Focused Summary of
Asthma Guidelines (2021)
Pocket Guide for Clinicians
For adults and children ages 12+ years

This brief clinical guide for the management
of asthma is based on the Expert Panel
Report 3 and 4 (draft) and GINA 2020 report
and other current asthma research.
Use caution in assessing asthma symptoms.
Many patients do not report "normal"
symptoms and may ration inhaler use even
when symptomatic. Consider using an
approach like the following, and do not rely
on frequency of SABA use as a conclusive
measure of asthma control.
In general over the past 1 to 4 weeks:
1. How many days a week do you have any
symptoms of recurrent coughing,
wheezing, chest tightness/pain or
repetitive throat clearing?
2. How many nights a week do you wake
up from your asthma symptoms?
3. Has asthma limited your activity in any
way lately?
4. What medication are you currently taking
for your asthma and how do you take it?
5. How many times did you need to use
your rescue inhaler for symptoms?
6. Do you always take your rescue inhaler
when you have symptoms or do you
wait?
COVID-19 guidance: avoid nebulizers or
spirometry when possible to prevent
aerosolizing virus.
Help us help you: For additional
updated copies of this guide, scan
the QR code to download, or go to:
https://digitalcommons.uri.edu/oerhealthcare-asthma/1
Copyright J.R. Mammen
Free for any non-commercial distribution.

Management of Persistent Asthma in Individuals Ages 12 Years and Older

Intermittent
Asthma

Consult with asthma specialist if Step 4 or higher is needed.
Reassess uncontrolled asthma every 2 to 6 weeks until good control is achieved.

ICS = inhaled corticosteroid (ICS+LABA indicates combined/concomitant use of both medications)
LABA = long acting beta agonist
LAMA = long acting muscarinic agonist
LTRA = leukotriene receptor agonist
STEP 3
OCS = oral systemic corticosteroid
SABA = short acting beta agonist
Moderate
Persistent
STEP 2

Mild Persistent

STEP 1
Intermittent

Preferred (EPR4):
•

Preferred EPR4 & GINA:
•

Daily low-dose ICS
and PRN SABA

•

PRN low-dose ICS
taken when SABA
used

PRN SABA

Preferred options (GINA):
•

PRN ICS+LABA

•

PRN low-dose ICS
taken when SABA
used

For acute symptoms:
2-8 puffs albuterol or 1
nebulizer; up to 3 treatments
@ 20 minute intervals PRN;
may need OCS

Preferred EPR4 & GINA:
•

PRN ICS+LABA

Daily LTRA and PRN
SABA

Moderate Persistent

Preferred EPR4 & GINA:
•

Low-dose *SMART

Preferred EPR4 & GINA:
•

Medium-dose
*SMART

Daily medium to high
dose ICS+LABA and
LAMA and PRN
SABA

Alternative options:

•

Daily medium-dose
ICS and PRN SABA

•

•

•

Daily low-dose
ICS+LABA and PRN
SABA

Daily medium-dose
ICS+LABA and PRN
SABA

Daily high-dose
ICS+LABA and PRN
SABA

•

Daily higher-dose
ICS+LABA and PRN
SABA

•

Daily high-dose ICS
and LTRA and PRN
SABA

•

Daily medium-dose
ICS+LAMA and PRN
SABA

•

For other options:
see guidelines

•

Alternative options:
•

Severe Persistent

STEP 4

Alternative options:

Preferred option (GINA):
•

STEP 5+

•

Daily low-dose
ICS+LAMA and PRN
SABA
Daily low-dose ICS
and LTRA and PRN
SABA

Alternative options:

FDA issued Boxed Warning for
montelukast in March 2020

*SMART - Single Maintenance and Reliever Therapy (currently off label in U.S.): Preferred for all patients at step 3 to 4;
SMART is combined ICS + formoterol (LABA) given daily for control PLUS as needed for symptoms (up to 12 total puffs per day for > 12 years age).

Classifying Asthma Severity in Individuals Ages 12 Years and Older
Assess severity BEFORE start of controller therapy based on symptoms, OR estimated based on level of stepwise therapy PLUS current level of control.

Severe Persistent

Intermittent

Mild Persistent

Moderate Persistent

Symptoms:
Days: 2 days/wk or less
Wake up: <2/month
Activity: no limitations
PEF or FEV1: > 80%
SABA: ≤2 time/week

Symptoms:
Days: >2 days/wk, not daily
Wake up: 3 - 4/month
Activity: minor limitations
PEF or FEV1: > 80%
SABA: >2 time/week

Symptoms:
Days: everyday (but not throughout the day)
Wake up: >1/week, but not nightly; *(≥4/week is VPC)
Activity: some limitations
PEF or FEV1: 60 - 80%
SABA: Daily

Well controlled

Not well controlled (NWC)

oral/systemic steroid use > 1 x year

Symptoms:
Days: throughout the day
Wake up: often 7x week
Activity: extremely limited
PEF or FEV1: < 60%
SABA: Several times daily

Very poorly controlled (VPC)

Assess and document BOTH severity and control at every visit. Control corresponds with highest level of current symptoms in any symptom box.

Classifying Asthma Control in Individuals Ages 12 Years and Older
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